Ribociclib
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer.[6] Ribociclib is a kinase inhibitor.[7][8] It was developed by Novartis and Astex Pharmaceuticals.[9]
| Clinical data | |
|---|---|
| Trade names | Kisqali |
| Other names | LEE 011 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617008 |
| License data |
|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | Unknown |
| Protein binding | ~70% |
| Metabolism | Liver (CYP3A4) |
| Elimination half-life | 32.0 (29.7–54.7) hrs |
| Excretion | 69% feces, 23% urine |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| ECHA InfoCard | 100.234.566 |
| Chemical and physical data | |
| Formula | C23H30N8O |
| Molar mass | 434.548 g·mol−1 |
| 3D model (JSmol) |
|
| |
| |
The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash.[5]
Ribociclib was approved by the US Food and Drug Administration (FDA) in March 2017,[10][11] by the European Medicines Agency (EMA) in August 2017,[5][12] and for use in the National Health Service (NHS) by National Institute for Health and Care Excellence (NICE) in February 2021.[7][13]
Medical uses edit
In the United States, it is indicated for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy in postmenopausal women or in men.[4][10]
In the European Union, it is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.[5] In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist.[5]
Side effects edit
The most common side effects in studies were decreased blood cell counts, mainly neutropenia (in 75% of patients, as compared to 5% under placebo), but also anemia (18% vs. 5%). Gastrointestinal disorders were also common, for example nausea (52% vs. 29%) and diarrhea (35% vs. 22%), as was alopecia (33% vs. 16%). The drug also increases the QT interval and liver enzymes (alanine transaminase, aspartate transaminase).[6][12]
The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhoea, constipation, tiredness, hair loss and rash.[5] The most common severe side effects include infections, low levels of red and white blood cells, vomiting, abnormal blood tests for liver function and low levels of phosphate in the blood (hypophosphataemia).[5]
Interactions edit
As ribociclib is mainly metabolized by the liver enzyme CYP3A4, inhibitors of this enzyme increase its concentrations in the body and could potentiate side effects and toxicity. Examples of such inhibitors include ketoconazole and similar antifungal drugs, ritonavir, clarithromycin, as well as grapefruit. Conversely, drugs that induce CYP3A4, such as rifampicin and St John's Wort, can decrease ribociclib concentrations.[6][12]
Ribociclib itself is a moderate to strong CYP3A4 inhibitor and therefore can increase concentrations of other drugs that share this metabolism, as has been shown with midazolam. It also inhibits a number of transporter proteins and could thus theoretically interfere with the transport of other drugs in the body. It could also amplify QT prolongation of other drugs such as antiarrhythmics, clarithromycin, and haloperidol.[6][12]
Pharmacology edit
Pharmacodynamics edit
Cyclin-dependent kinases (CDKs) 4 and 6 are enzymes that have been shown to promote cell division and multiplication in both normal and cancer cells. Many cancer cells have shown abnormalities that increase the activity of CDK, leading to the inactivation of certain tumor suppressor genes.[14][15]
When used in combination with other drugs such as an ALK or an MEK inhibitor, ribociclib has been shown to have a synergistic effect, resulting in improved responses.[16][17] Again, this is likely a result of "crosstalk" between signaling pathways. Simply blocking one pathway in cancer tumorigenesis can sometimes result in "tumor compensation", where the tumor compensates for the blocked signaling pathway by utilizing other pathways to survive. By blocking several pathways at once, it is thought that the tumor is less able to compensate, and a greater anti-tumor response is often observed. Utilizing ribociclib in combination with other agents has been shown to reduce the development of resistance to these agents.[14]
Pharmacokinetics edit
The percentage of ribociclib absorbed in the gut has not been determined. Highest blood plasma levels are reached after one to four hours; and after repeated dosage, steady state concentrations are reached after about eight days. Food intake has no effect on absorption rates. When in the bloodstream, about 70% of ribociclib is bound to plasma proteins.[6][12]
The substance is mainly metabolized by CYP3A4 and subsequently by various phase II enzymes, resulting in a large number of metabolites. Those with highest blood plasma concentrations in humans are called CCI284 (an unspecified N-hydroxylation product), LEQ803 (the N-demethylation product) and M1 (a glucuronide). All metabolites have negligible clinical activity.[6][12]
Ribociclib has a slight tendency to accumulate in the body. It is eliminated with an average biological half-life of 32 hours, mostly (69%) via the feces, but also (23%) via the urine. The unchanged drug accounts for 17% of the substance in the feces and 12% of the substance in the urine, the rest being metabolites.[6][12]
Chemistry edit
Ribociclib is used in form of its succinate salt. It is a slightly hygroscopic yellow to brown crystalline powder that is soluble in aqueous acids.[18]
History edit
Ribociclib is the only CDK4/CDK6 inhibitor with a proven benefit on overall survival across all three phase III trials of the MONALEESA clinical program with different endocrine therapy partners, regardless of menopausal status or line of therapy.[19][unreliable medical source?] The European Society of Medical Oncology (ESMO) assigned the highest score on the 'Magnitude of Clinical Benefit Scale' for Kisqali.[20][failed verification]
In the clinical trial relevant for the drug's approval, ribociclib significantly improved progression-free survival, that is, the time span the cancer did not get worse. For participants receiving placebo plus letrozole, progression-free survival was 16 months on average, while under ribociclib plus letrozole, progression-free survival was 25 months as of the January 2017 analysis.[12] The study is scheduled to run until September 2020.[21]
References edit
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Search Page - Drug and Health Product Register". 23 October 2014.
- ^ a b "Kisqali- ribociclib tablet, film coated". DailyMed. 4 May 2023. Retrieved 9 July 2023.
- ^ a b c d e f g "Kisqali EPAR". European Medicines Agency (EMA). 31 March 2023. Retrieved 9 July 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b c d e f g FDA Professional Drug Information on Kisqali. Accessed 8 September 2017.
- ^ a b "Thousands of breast cancer patients to have routine access to NICE-approved drug combination". NICE (Press release). Retrieved 8 March 2021.
- ^ "Kisqali (ribociclib) Treatment: HR+/HER2- mBC". Novartis. Retrieved 24 August 2021.
- ^ "Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer" (Press release). Novartis. 1 November 2016.
- ^ a b "Kisqali (ribociclib) Tablets". U.S. Food and Drug Administration (FDA). 28 March 2017. Retrieved 9 July 2023.
- ^ "FDA Clears Novartis Kisqali for Combination Breast Cancer Therapy". Genetic Engineering and Biotechnology News. 14 March 2017. Retrieved 9 July 2023.
- ^ a b c d e f g h "Kisqali: EPAR – Product Information" (PDF). European Medicines Agency. 31 August 2017.
- ^ "Life-extending drug for incurable breast cancer approved for NHS use". The Guardian. 26 February 2021. Retrieved 8 March 2021.
- ^ a b Samson K (2014). "LEE011 CDK Inhibitor Showing Early Promise in Drug-Resistant Cancers". Oncology Times. 36 (3): 39–40. doi:10.1097/01.COT.0000444043.33304.c1.
- ^ Kim S, Loo A, Chopra R, Caponigro G, Huang A, Vora S, et al. (2014). "Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6- Reactivating Rb in cancer". Molecular Cancer Therapeutics. 12 (11_Supplement): PR02. doi:10.1158/1535-7163.TARG-13-PR02.
- ^ Sosman JA, Kittaneh M, Lolkema MP, Postow MA, Schwartz G, Franklin C, et al. (2014). . Journal of Clinical Oncology. 32 (15 Suppl): 9009. doi:10.1200/jco.2014.32.15_suppl.9009. Archived from the original on 7 October 2015. Retrieved 14 January 2017.
- ^ Wood AC, Krytska K, Ryles H, Sano R, Li N, King F, et al. (2014). "Abstract 1000: Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma". Cancer Research. 74 (19 Supplement): 1000. doi:10.1158/1538-7445.AM2014-1000.
- ^ "Kisqali: EPAR – Public assessment report" (PDF). European Medicines Agency. 31 August 2017.
- ^ "Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer". Novartis (Press release). Retrieved 19 October 2021.
- ^ "ESMO-Magnitude of Clinical Benefit Scale". ESMO. Retrieved 19 October 2021.
- ^ Clinical trial number NCT01958021 for "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)" at ClinicalTrials.gov